Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:01):
We're gonna look at b venom and believe it or
not cancer. So the claim that was made while back
is the b venom can kill one hundred percent of
aggressive breast cancer cells in less than sixty minutes, and
this is something that people were looking at. A claim
that was made online from a twenty twenty study by
the Harry Perkins Institute in Australia. The study found that
(00:23):
men littan, a key component of b venom, can disrupt
the membranes of cancer cells, leading to the rapid destruction.
The research show the low doses of b venom, when
combined with chemotherapy drugs, effectively targeted triple negative breast cancer cells,
a particularly aggressive and hard to treat form. The process
was remarkably flat fast, with significant cell death. This of
(00:46):
course sparked interest in what they call appy therapy, the
use of b products for medicinal purposes. However, the finding
is preliminary, and of course it's limited because it's an
in vitro test tube study. It does not mean b
venom is a cue or safe treatment for humans, and
vitro studies are really like the beginning of these type
of studies. You go from here to animal studies like
(01:07):
rats to see how the physiology starts interacting with these
two components. Because when you have two components, like trying
to figure out a medicine for like b venom and
a cancer cell, the physiology of a human for instance,
will interact and cause possibly changes and how the b
venom would integrate with the or attack the cancer cells.
(01:30):
So in vitro just kind of starts the ball rolling
and gives us questions. It does not mean b venom
is a cure or safe treatment. Human biobiology is far
more complex, so you got things to think about like
dosage and delivery and side effects. Clinical trials are essential
to determine efficacy and safety, and as of July twenty seventh,
no such trials have conclusively validated b venom for cancer therapy,
(01:53):
but there are exploring it, and you're looking at synthetic
versions of malidant to mitigate risks. So don't fall for
this and saeational headline which exaggerates the results for attention
in a common tactic and health related media. The science
is intriguing, though, and it's critical to review more peer
reviewed studies.